
|Videos|January 16, 2014
The Immunogenic Potential of Biosimilars: Should Health Care Providers Be Concerned?
Immunogenicity is an important consideration for all biologics, not just for biosimilars, noted Steven Lucio, Senior Director, Clinical Solutions and Pharmacy Program Development at Novation.
Advertisement
Immunogenicity is an important consideration for all biologics, not just for biosimilars, noted Steven Lucio, Senior Director, Clinical Solutions and Pharmacy Program Development at Novation.
This video was shot at the 2013 Academy of Managed Care Pharmacy in San Antonio, Texas.
Advertisement
Related Content
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Pharmacists at the Forefront: Initiating, Monitoring, and Identifying Candidates for VMAT2 Therapy
2
FDA Accepts NDA for AD109 for Treatment of Adults With Obstructive Sleep Apnea
3
Up to 5 Cups of Coffee Daily Safe—and Benficial—for Most Adults
4
Could VER-01 Redefine the Role of Cannabis in Chronic Pain Care?
5





































































































